TY - JOUR
T1 - Coffee and tea consumption and risk of pre- and postmenopausal breast cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort study
AU - Bhoo-Pathy, Nirmala
AU - Peeters, Petra H.M.
AU - Uiterwaal, Cuno S.P.M.
AU - Bueno-de-Mesquita, H. Bas
AU - Bulgiba, Awang M.
AU - Bech, Hammer H.
AU - Overvad, Kim
AU - Tjønneland, Anne
AU - Olsen, Anja
AU - Clavel-Chapelon, Françoise
AU - Fagherazzi, Guy
AU - Perquier, Florence
AU - Teucher, Birgit
AU - Kaaks, Rudolf
AU - Schütze, Madlen
AU - Boeing, Heiner
AU - Lagiou, Pagona
AU - Orfanos, Philippos
AU - Trichopoulou, Antonia
AU - Agnoli, Claudia
AU - Mattiello, Amalia
AU - Palli, Domenico
AU - Tumino, Rosario
AU - Sacerdote, Carlotta
AU - Van Duijnhoven, Franzel J.B.
AU - Braaten, Tonje
AU - Lund, Eiliv
AU - Skeie, Guri
AU - Redondo, María Luisa
AU - Buckland, Genevieve
AU - Pérez, Sánchez J.S.
AU - Chirlaque, Maria Dolores
AU - Ardanaz, Eva
AU - Amiano, Pilar
AU - Wirfält, Elisabet
AU - Wallström, Peter
AU - Johansson, Ingegerd
AU - Nilsson, Maria M.
AU - Khaw, Kay Tee
AU - Wareham, Nick
AU - Allen, Naomi E.
AU - Key, Timothy J.
AU - Rinaldi, Sabina
AU - Romieu, Isabelle
AU - Gallo, Valentina
AU - Riboli, Elio
AU - Van Gils, Carla H.
N1 - Publisher Copyright:
© Bhoo-Pathy et al.
PY - 2015/1/31
Y1 - 2015/1/31
N2 - Introduction: Specific coffee subtypes and tea may impact risk of pre- and post-menopausal breast cancer differently. We investigated the association between coffee (total, caffeinated, decaffeinated) and tea intake and risk of breast cancer. Methods: A total of 335,060 women participating in the European Prospective Investigation into Nutrition and Cancer (EPIC) Study, completed a dietary questionnaire from 1992 to 2000, and were followed-up until 2010 for incidence of breast cancer. Hazard ratios (HR) of breast cancer by country-specific, as well as cohort-wide categories of beverage intake were estimated. Results: During an average follow-up of 11 years, 1064 premenopausal, and 9134 postmenopausal breast cancers were diagnosed. Caffeinated coffee intake was associated with lower risk of postmenopausal breast cancer: adjusted HR = 0.90, 95% confidence interval (CI): 0.82 to 0.98, for high versus low consumption; P trend = 0.029. While there was no significant effect modification by hormone receptor status (P = 0.711), linear trend for lower risk of breast cancer with increasing caffeinated coffee intake was clearest for estrogen and progesterone receptor negative (ER-PR-), postmenopausal breast cancer (P = 0.008). For every 100 ml increase in caffeinated coffee intake, the risk of ER-PR- breast cancer was lower by 4% (adjusted HR: 0.96, 95% CI: 0.93 to 1.00). Non-consumers of decaffeinated coffee had lower risk of postmenopausal breast cancer (adjusted HR = 0.89; 95% CI: 0.80 to 0.99) compared to low consumers, without evidence of dose-response relationship (P trend = 0.128). Exclusive decaffeinated coffee consumption was not related to postmenopausal breast cancer risk, compared to any decaffeinated-low caffeinated intake (adjusted HR = 0.97; 95% CI: 0.82 to 1.14), or to no intake of any coffee (HR: 0.96; 95%: 0.82 to 1.14). Caffeinated and decaffeinated coffee were not associated with premenopausal breast cancer. Tea intake was neither associated with pre- nor post-menopausal breast cancer. Conclusions: Higher caffeinated coffee intake may be associated with lower risk of postmenopausal breast cancer. Decaffeinated coffee intake does not seem to be associated with breast cancer.
AB - Introduction: Specific coffee subtypes and tea may impact risk of pre- and post-menopausal breast cancer differently. We investigated the association between coffee (total, caffeinated, decaffeinated) and tea intake and risk of breast cancer. Methods: A total of 335,060 women participating in the European Prospective Investigation into Nutrition and Cancer (EPIC) Study, completed a dietary questionnaire from 1992 to 2000, and were followed-up until 2010 for incidence of breast cancer. Hazard ratios (HR) of breast cancer by country-specific, as well as cohort-wide categories of beverage intake were estimated. Results: During an average follow-up of 11 years, 1064 premenopausal, and 9134 postmenopausal breast cancers were diagnosed. Caffeinated coffee intake was associated with lower risk of postmenopausal breast cancer: adjusted HR = 0.90, 95% confidence interval (CI): 0.82 to 0.98, for high versus low consumption; P trend = 0.029. While there was no significant effect modification by hormone receptor status (P = 0.711), linear trend for lower risk of breast cancer with increasing caffeinated coffee intake was clearest for estrogen and progesterone receptor negative (ER-PR-), postmenopausal breast cancer (P = 0.008). For every 100 ml increase in caffeinated coffee intake, the risk of ER-PR- breast cancer was lower by 4% (adjusted HR: 0.96, 95% CI: 0.93 to 1.00). Non-consumers of decaffeinated coffee had lower risk of postmenopausal breast cancer (adjusted HR = 0.89; 95% CI: 0.80 to 0.99) compared to low consumers, without evidence of dose-response relationship (P trend = 0.128). Exclusive decaffeinated coffee consumption was not related to postmenopausal breast cancer risk, compared to any decaffeinated-low caffeinated intake (adjusted HR = 0.97; 95% CI: 0.82 to 1.14), or to no intake of any coffee (HR: 0.96; 95%: 0.82 to 1.14). Caffeinated and decaffeinated coffee were not associated with premenopausal breast cancer. Tea intake was neither associated with pre- nor post-menopausal breast cancer. Conclusions: Higher caffeinated coffee intake may be associated with lower risk of postmenopausal breast cancer. Decaffeinated coffee intake does not seem to be associated with breast cancer.
UR - http://www.scopus.com/inward/record.url?scp=84924263203&partnerID=8YFLogxK
U2 - 10.1186/s13058-015-0521-3
DO - 10.1186/s13058-015-0521-3
M3 - Article
C2 - 25637171
AN - SCOPUS:84924263203
SN - 1465-5411
VL - 17
JO - Breast Cancer Research
JF - Breast Cancer Research
IS - 1
M1 - 15
ER -